SNDX: Maintenance growth and frontline trials support a new phase of pipeline expansion
Syndax Pharmaceuticals (SNDX) anticipates revenue growth from its drug Revuforj, driven by new patient starts and extended post-transplant maintenance, with a greater financial impact expected in 2027. The company is also advancing its next growth phase through frontline trials and distinct EGFR and next-generation menin programs. This information is based on insights from the Stifel 2026 Healthcare Conference.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syndax Pharmaceuticals, Inc.- SNDX
Pomerantz LLP is investigating potential securities fraud claims against Syndax Pharmaceuticals, Inc. on behalf of its investors. This follows a 2.59% drop in Syndax's stock price on October 12, 2026, after the company announced that its MAXPIRe Phase 2 trial of axatilimab in idiopathic pulmonary fibrosis (IPF) did not meet its primary endpoint. Investors are encouraged to contact Danielle Peyton at Pomerantz LLP for more information.
CenterBook Partners LP Makes New $5.14 Million Investment in Syndax Pharmaceuticals, Inc. $SNDX
CenterBook Partners LP has made a new $5.14 million investment in Syndax Pharmaceuticals (NASDAQ:SNDX), acquiring 273,253 shares in the third quarter. Despite the investment, Syndax Pharmaceuticals faces mixed sentiment from analysts, with a "Moderate Buy" consensus but missed earnings per share estimates for the last quarter. The company's stock is trading near its 52-week low, while institutional investors continue to adjust their stakes.
State Street reports a passive stake above 5% in Syndax Pharmaceuticals (SNDX).
State Street Corporation has reported a passive beneficial ownership stake of 5.2% in Syndax Pharmaceuticals Inc. (SNDX), holding 4,653,172 common shares as of September 30, 2026. This disclosure was made via a SCHEDULE 13G SEC filing, indicating shared voting power over 4,436,323 shares and shared dispositive power over all 4,653,172 shares. The filing classifies State Street as a parent holding company acting in the ordinary course of business, not for the purpose of influencing control.
Syndax Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Syndax Pharmaceuticals announced an inducement award for its new Chief Financial Officer, Aaron A. Ondrey, consisting of options to purchase up to 270,000 shares of common stock. The award, with an exercise price of $9.55 per share, will vest over four years and was approved in accordance with NASDAQ Listing Rule 5635(c)(4). This grant is tied to Mr. Ondrey's employment, which commenced on November 9, 2026.
Syndax Pharmaceuticals, Inc. (SNDX) Seasonal Returns Chart - Yahoo Finance
This article provides a seasonal returns chart for Syndax Pharmaceuticals, Inc. (SNDX), displaying the average monthly price return from 2016 to 2026. The stock's current real-time price is shown, along with after-hours trading information. The page also includes general market data for Canadian and international markets.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syndax Pharmaceuticals, Inc.- SNDX
Pomerantz LLP is investigating claims on behalf of investors of Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) following a significant drop in stock price. This investigation comes after Syndax announced on October 12, 2026, that its MAXPIRe Phase 2 trial of axatilimab for idiopathic pulmonary fibrosis did not meet its primary endpoint, causing shares to fall by 2.59%. The firm encourages affected investors to contact them to learn more about joining a potential class action.
Syndax Pharmaceuticals stock: ASH to feature 19 drug abstracts
Syndax Pharmaceuticals will present 19 drug abstracts at the American Society of Hematology (ASH) 2026 Annual Meeting, including seven oral presentations for its drug revumenib. The company will also host an investor event on December 14 to discuss data from its Revuforj and Niktimvo programs. These presentations will include updated results for acute myeloid leukemia and long-term efficacy and safety data for chronic graft-versus-host disease.
Syndax Pharmaceuticals Is Down 51% Even Though Sales Rose
Syndax Pharmaceuticals' stock has fallen 50.9% this year despite strong Q1 and Q2 updates on Revuforj and Niktimvo, primarily due to the failure of axatilimab in its Phase 2 IPF trial. The current share price of US$10.45 is below a "Fair Value" derived from a bullish narrative that anticipates Revuforj and Niktimvo developing into larger oncology franchises and an expanding pipeline. Investors are left to weigh whether the dip is a short-term reaction to the IPF disappointment against the potential commercial momentum of its core oncology drugs.
Syndax Pharmaceuticals Inc (SNDX) (Q3 2026) Earnings Call Highlights: Revenue Surges 82% as ...
Syndax Pharmaceuticals reported an 82% year-over-year revenue surge to $83.3 million in Q3 2026, driven by strong performance from ReviForge and Niktimvo. ReviForge net revenue increased 90% year-over-year, while Niktimvo grew 47%. The company maintains a strong cash position of $551 million, fully funding its commercial and R&D priorities, despite facing short-term revenue headwinds from patients pausing treatment for stem cell transplants and intensifying competition in the menin inhibitor space.
Syndax Pharmaceuticals stock hits 52-week low at 12.79 USD By Investing.com
Syndax Pharmaceuticals (SNDX) stock recently hit a 52-week low of $12.79, trading down approximately 50% from its high and 32% year-to-date. Despite this decline, InvestingPro analysis suggests the stock is undervalued, while the company reported strong Q3 2026 revenues of $83.3 million, driven by Revuforj and Niktimvo sales. Analysts have maintained "Buy" and "Outperform" ratings, albeit with slightly adjusted price targets, indicating a mixed outlook for the biopharmaceutical firm.
Medical experts will join Syndax leaders to discuss data from a blood-disease meeting.
Syndax Pharmaceuticals will host an in-person investor event and live webcast on December 14, 2026, during the ASH Annual Meeting. The event will feature members of Syndax management and key opinion leaders discussing data presented at the meeting. A live webcast and limited-time replay will be available on the Investor section of the company's website.
Five new hires get Syndax options that vest over four years
Syndax Pharmaceuticals (Nasdaq: SNDX) has granted inducement stock options for up to 213,500 common shares to five new employees under its 2023 Inducement Plan. These options are designed to vest over a four-year period, with an initial 25% vesting on the first anniversary of the commencement date, followed by monthly vesting of 1/48th of the remaining shares over the subsequent 36 months, conditional on continued employment. This move aims to attract and retain talent while aligning employee interests with the company's long-term growth.
Syndax Pharmaceuticals stock hits 52-week low at 12.79 USD
Syndax Pharmaceuticals (SNDX) stock has fallen to a 52-week low of $12.79, representing a 32% year-to-date decline and nearly 50% down from its high. Despite this downturn, InvestingPro analysis suggests the stock is undervalued, and the company recently reported strong Q3 2026 revenues driven by its lead drugs, Revuforj and Niktimvo, although it posted a wider-than-expected adjusted loss per share.
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Syndax Pharmaceuticals announced that it granted inducement awards to five new employees to purchase up to 213,500 shares of common stock under its 2023 Inducement Plan. These stock options will vest over four years, with a quarter vesting on the one-year anniversary and the remainder monthly over 36 months, contingent on continued employment. Syndax is a commercial-stage biopharmaceutical company focused on innovative cancer therapies, including its FDA-approved drugs Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr).
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Syndax Pharmaceuticals announced that it granted inducement awards to five new employees, allowing them to purchase up to 213,500 shares of common stock under the company's 2023 Inducement Plan. These stock options will vest over four years, with 25% vesting on the one-year anniversary and the remainder vesting monthly thereafter. Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company focused on innovative cancer therapies, including its FDA-approved drugs Revuforj and Niktimvo.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syndax Pharmaceuticals, Inc.- SNDX
Pomerantz LLP is investigating potential securities fraud claims against Syndax Pharmaceuticals, Inc. (SNDX) on behalf of its investors. This investigation follows a significant drop in Syndax's stock price on October 12, 2026, after the company announced that its MAXPIRe Phase 2 trial of axatilimab for idiopathic pulmonary fibrosis (IPF) did not meet its primary endpoint. Investors who believe they have been affected are encouraged to contact the law firm.
Top 5 Healthcare Sales Expansion Leaders: Hinge Health (NYSE:HNGE), Syndax Pharmaceuticals (NASDAQ:SNDX), Recursion Pharmaceuticals (NASDAQ:RXRX) and More
This article identifies the top five healthcare and biotech firms based on their year-over-year sales growth in Q3 2026. Recursion Pharmaceuticals led with 258.5% growth, followed by Syndax Pharmaceuticals, Hinge Health, Axsome Therapeutics, and Neurocrine Biosciences. The report details each company's financial performance, key drivers for their sales expansion, and future outlook.
What Syndax Pharmaceuticals (SNDX) Said on Its Q3 Earnings Call
Syndax Pharmaceuticals reported strong Q3 2026 results with total revenue of $83.3 million, an 82% increase year-over-year, driven by Revuforj and Niktimvo sales. Revuforj sales grew significantly due to new patients and post-transplant use, while Niktimvo expanded its market share in chronic graft-versus-host disease. The company also outlined upcoming clinical trial results and pipeline plans, maintaining its financial guidance for 2026.
Syndax Pharmaceuticals (SNDX) Stock May Be Rich After Revuforj Award Win
Syndax Pharmaceuticals (SNDX) stock is down significantly year-to-date, prompting questions about its valuation relative to sales, especially after its drug Revuforj won a Prix Galien USA award. While the stock's P/S ratio of 4.6x is below industry averages, it screens as overvalued when considering its specific risk profile and fundamentals. The award for Revuforj suggests investors may be placing a premium on perceived product quality rather than just immediate revenue.
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Stock Rated "Moderate Buy" by Sell-Side Analysts
Sell-side analysts have maintained a "Moderate Buy" consensus for Syndax Pharmaceuticals (NASDAQ:SNDX), with an average 12-month price target of $41.80, significantly above its current share price of $13.10. The company reported an 81.9% year-over-year increase in third-quarter revenue to $83.3 million, surpassing estimates, primarily driven by Revuforj and Niktimvo. Despite the strong revenue growth, Syndax remains unprofitable, posting a $0.55-per-share loss, and faces execution risks due to pipeline setbacks and a CFO transition.
H.C. Wainwright lowers Syndax Pharmaceuticals price target to $36
H.C. Wainwright has lowered its price target for Syndax Pharmaceuticals (NASDAQ: SNDX) to $36 from $38, while maintaining a Buy rating. The adjustment comes despite strong commercial growth for the company's drugs, Revuforj and Niktimvo, with total revenue reaching $83.3 million, an 82% year-over-year increase. Analysts anticipate that Syndax will not achieve profitability this year, noting weak gross profit margins despite the revenue momentum.
Syndax Misses On EPS But Revuforj Rebound And Higher Niktimvo Margin Guide Sharpen The Commercial Story As Pipeline Setbacks Hang Over The Stock
Syndax Pharmaceuticals reported a third-quarter EPS miss but exceeded revenue estimates, driven by strong sales of Revuforj and Niktimvo. Despite commercial successes like increased patient starts for Revuforj and higher margin guidance for Niktimvo, pipeline setbacks, including the failure of an IPF trial and a cGVHD delay, have negatively impacted the stock. The company's stock is currently trading near its 52-week low, with investor sentiment remaining negative as the market awaits crucial ASH data.
Syndax: Q3 Earnings Snapshot
Syndax Pharmaceuticals Inc. (SNDX) reported a third-quarter loss of $49.4 million, or 55 cents per share, missing Wall Street expectations of a 52 cents per share loss. However, the biopharmaceutical company exceeded revenue forecasts, posting $83.3 million against an anticipated $81.1 million. The results were generated by Automated Insights using data from Zacks Investment Research.
Syndax Pharmaceuticals earnings missed by $0.07, revenue topped estimates
Syndax Pharmaceuticals reported a third-quarter EPS of $-0.55, missing analyst estimates by $0.07, while its revenue of $83.3M surpassed the consensus estimate of $82.41M. The company's stock price closed at $13.10, showing a decline of -33.70% in the last three months and -4.80% in the last 12 months. InvestingPro assesses Syndax Pharmaceuticals's financial health as "fair performance."
Syndax Pharmaceuticals Q3 2026 Earnings Call Is Live
Syndax Pharmaceuticals's Q3 2026 earnings call has just begun, allowing executives to discuss the latest financial results and answer questions from analysts. This event is crucial for investors following SNDX, as management commentary on future demand, margins, or capital spending can significantly impact market sentiment. Attendees will hear explanations behind the reported numbers and potentially receive surprising news.
Syndax Posts $83.3 Million in Q3 2026 Revenue as Net Loss Narrows
Syndax Pharmaceuticals reported $83.298 million in revenue for Q3 2026, a significant increase from $45.871 million in the same quarter of 2025. This revenue included $60.743 million from product sales (Revuforj) and $22.555 million from collaboration revenue (Niktimvo). The company also narrowed its net loss attributable to common stockholders to $49.433 million, or $0.55 per share, down from $60.715 million, or $0.70 per share, in the prior year.
Syndax Pharmaceuticals (SNDX) Stock Price, Chart & Analysis
This article provides a detailed analysis of Syndax Pharmaceuticals (SNDX) stock, covering its current price, market capitalization, growth metrics, and financial health. It includes a quality score, dividend policy, and valuation insights, as well as an assessment based on "Buffett and Lynch" investment philosophies. The report concludes with potential future price scenarios under pessimistic, base, and optimistic growth assumptions.
Syndax Pharmaceuticals director Dennis Podlesak sells $113,716 in stock
Dennis Podlesak, a director at Syndax Pharmaceuticals Inc (NASDAQ:SNDX), sold 8,000 shares of common stock worth $113,716 on October 29, 2026, after exercising options. The sale was executed under a Rule 10b5-1 trading plan. This transaction occurred as Syndax shares trade near their 52-week low, and comes amidst mixed analyst reactions to recent clinical trial results for one of the company's drugs.
Syndax Pharmaceuticals director Dennis Podlesak sells $113,716 in stock By Investing.com
Dennis Podlesak, a director at Syndax Pharmaceuticals Inc, sold 8,000 shares of common stock for $113,716 on October 29, 2026, after exercising options. The transaction was made under a Rule 10b5-1 trading plan and occurred as Syndax shares traded near their 52-week low. This insider sale follows recent news of a failed Phase 2 trial for axatilimab, leading to mixed analyst ratings for the company.
Syndax Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144
This document serves as a Form 144 notice, indicating a proposed sale of securities by a reporting person of Syndax Pharmaceuticals (SNDX) in accordance with Rule 144. The filing specifies the type of security as common stock and details the transactions involving the sale.
A director plans to sell 8,000 shares of Syndax Pharmaceuticals (SNDX).
Dennis G. Podlesak, a director at Syndax Pharmaceuticals (SNDX), intends to sell 8,000 common shares acquired through stock options. The proposed sale, valued at approximately $114,560.00, is scheduled for October 29, 2026, with Morgan Stanley Smith Barney LLC acting as the broker. This information was filed via a Form 144 notice with the SEC.
SNDX Q3'26 Earnings: EPS estimate is (0.49) USD
Syndax Pharmaceuticals, Inc. (SNDX) is scheduled to announce its Q3'26 financial results on November 02, after the market closes, with earnings expected at 4:01 PM ET. Analysts project revenue of $81.75 million and an EPS of ($0.49) for the quarter. The article provides a table comparing reported and estimated revenue and EPS, along with surprise percentages for recent quarters.
Syndax Announces Participation in November Investor Conferences
Syndax Pharmaceuticals (Nasdaq: SNDX) announced that its CEO and management team will participate in four upcoming investor conferences in November 2026: Guggenheim, Stifel, UBS Global Biopharma, and Jefferies London Healthcare. The company will hold fireside chats at each event, with live webcasts and replays available on its investor website. Syndax is a commercial-stage biopharmaceutical company focused on innovative cancer therapies, including FDA-approved Revuforj® and Niktimvo™.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Syndax Pharma
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) after the company's Phase 2 MAXPIRe clinical trial failed to meet its primary endpoint, causing a stock price decline of over 15.7% on October 13, 2026. The firm encourages affected investors to connect with them to assist in the investigation into Syndax's securities.
Syndax to Announce Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 2, 2026
Syndax Pharmaceuticals will announce its third-quarter 2026 financial results and provide a business update on Monday, November 2, 2026. The company will host a conference call and live audio webcast at 4:30 p.m. ET on the same day. A replay of the call will be available on the Investors section of Syndax's website for 90 days.
At 4:30 p.m. ET on Nov. 2, Syndax will host its results call and webcast
Syndax Pharmaceuticals (SNDX) announced it will report its third quarter 2026 financial results and provide a business update on Monday, November 2, 2026. Management will host a conference call and live audio webcast at 4:30 p.m. ET on that day to discuss the results. The webcast and accompanying slides will be accessible through the company's investor website, with a replay available for 90 days.
Syndax Pharmaceuticals (SNDX) Set to Announce Quarterly Earnings on Monday
Syndax Pharmaceuticals (NASDAQ:SNDX) is scheduled to announce its Q3 2026 earnings after market close on Monday, November 2nd, with analysts anticipating a loss of $0.4848 per share and revenue of $81.91 million. This follows a Q2 2026 performance where the company missed expectations, reporting a $0.55-per-share loss against a $0.45 estimate, though revenue increased by 91.8% year-over-year. Despite trading near its 12-month low, Wall Street maintains a "Moderate Buy" rating with an average price target of $41.80.
Syndax to Announce Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 2, 2026
Syndax Pharmaceuticals (Nasdaq: SNDX) announced it will report its third quarter 2026 financial results and provide a business update on Monday, November 2, 2026. The company will host a conference call and live audio webcast at 4:30 p.m. ET on the same day to discuss the results and update. A replay of the call will be available on Syndax's website for 90 days.
Syndax Pharmaceuticals, Inc. Estimates – NASDAQ:SNDX
This article provides an overview of Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) financial data and analyst estimates available on TradingView. It allows users to explore reported financials and compare them against average, high, and low estimates, visualizing trends over time for income statements, balance sheets, and cash flow.
SNDX Q3'26 Earnings: revenue estimate is 81.91M USD
Syndax Pharmaceuticals, Inc. (SNDX) is expected to announce its Q3'26 results on October 29, with earnings disclosure anticipated at 8:00 AM ET (12:00 PM UTC). The revenue estimate for Q3'26 is $81.91 million USD, and the estimated EPS is ($0.49) USD. The article provides a comparison of reported versus estimated revenue and EPS for several quarters, including Q3'26.
Citi Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Maintains Target Price $57
Citi has reiterated its Buy rating on Syndax Pharmaceuticals (SNDX.US) and maintained its target price at $57. This indicates a continued positive outlook from Citi on the company's stock performance.
Syndax halts IPF development: Wainwright keeps USD 38 target for Syndax Pharmaceuticals stock
Syndax Pharmaceuticals has discontinued its Phase 2 MAXPIRe trial for axatilimab in idiopathic pulmonary fibrosis (IPF) after it failed to meet its primary endpoint, leading to a pipeline setback. Despite this, H.C. Wainwright has maintained a Buy rating and a USD 38 target for the stock. The company's second-quarter 2026 revenue increased significantly year-over-year, supported by strong commercial performance from Revuforj and collaboration revenue.
Syndax gets TIME recognition as Wainwright keeps USD 38 target for Syndax Pharmaceuticals stock
Syndax Pharmaceuticals' Revuforj was recognized on TIME's Best Inventions of 2026 list, boosting the company's commercial portfolio despite a setback in its axatilimab Phase 2 trial for idiopathic pulmonary fibrosis. H.C. Wainwright reiterated a Buy rating with a $38 price target, and investors are now focused on the commercial performance of Revuforj and Niktimvo, as well as upcoming Q3 results.
SNDX Investors with $100,000 in Losses Have Opportunity to Join Syndax Pharmaceuticals, Inc. Fraud Investigation with SBS Law
Schall, Brown & Schwartz LLP (SBS) has initiated an investigation into Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) following a significant stock drop. The investigation focuses on potential securities law violations after Syndax announced on October 12, 2026, that its Phase 2 MAXPIRe trial failed to meet its primary endpoint, causing shares to fall over 15.7%. SBS is encouraging investors who suffered losses to participate in the fraud investigation.
Syndax Pharmaceuticals (NASDAQ:SNDX) Reaches New 1-Year Low - Time to Sell?
Syndax Pharmaceuticals (NASDAQ:SNDX) shares dropped 4.9% to a new 52-week low of $12.95, significantly below its moving averages, and missed quarterly earnings expectations despite a 91.8% year-over-year revenue increase. However, analysts largely maintain a "Buy" rating with an average target price of $41.80, and major institutions like BlackRock and Bank of America have recently established positions in the company. Syndax Pharmaceuticals is a biopharmaceutical company specializing in cancer therapies, with its lead product Revuforj approved for acute leukemia.
Syndax Pharmaceuticals stock hits 52-week low at 12.98 USD By Investing.com
Syndax Pharmaceuticals (SNDX) stock has fallen to a 52-week low of $12.98, experiencing a nearly 20% decline in the past week. Despite this, InvestingPro analysis suggests the stock may be undervalued. Recent news indicates a mixed outlook from analysts, with Stifel, H.C. Wainwright, and Jefferies maintaining Buy ratings, while UBS adjusted its price target lower due to a decline in new patient starts for one of Syndax’s drugs, though still maintaining a Buy rating.
Syndax Pharmaceuticals stock hits 52-week low at 12.98 USD By Investing.com
Syndax Pharmaceuticals (SNDX) stock has fallen to a 52-week low of $12.98, experiencing a nearly 20% decline in the past week and an 8.53% drop over the year. Despite this, InvestingPro analysis suggests the stock is undervalued, and analysts from Stifel, H.C. Wainwright, and Jefferies maintain Buy ratings, citing potential in Niktimvo and upcoming trial data, even after a setback in the Phase 2 MAXPIRe trial for axatilimab. UBS also maintains a Buy rating, though it adjusted its price target due to a decline in new patient starts for Revuforj.
Syndax’s Revuforj® (revumenib) Named to TIME’s Best Inventions of 2026 List
Syndax Pharmaceuticals announced that its first-in-class menin inhibitor, Revuforj (revumenib), was selected by TIME as one of the "Best Inventions of 2026" in the Medical and Healthcare category. Revuforj is FDA-approved for adults and children one year and older with multiple types of relapsed or refractory acute leukemia, including those with KMT2A translocation and susceptible NPM1 mutation. The recognition highlights the drug's impact and innovation in treating aggressive forms of leukemia.
HC Wainwright keeps USD 38.00 target for Syndax Pharmaceuticals stock
HC Wainwright has maintained its USD 38.00 price target for Syndax Pharmaceuticals (SNDX) despite the company reporting a setback in its MAXPIRe Phase 2 trial for axatilimab. The clinical trial for idiopathic pulmonary fibrosis did not meet its primary endpoint, leading to the discontinuation of development in that indication. However, the firm continues to value Syndax's approved oncology products and chronic graft-versus-host disease programs, with the stock currently trading at EUR 12.14.